Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

Rhea-AI Summary

BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) taking place from February 19-22, 2023, in Seattle. The posters include:

• Poster 512: No Dose Adjustments for CYP3A4 Substrates with Bemnifosbuvir
• Poster 513: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated Transport

Atea focuses on developing oral therapies for severe viral diseases and utilizes a proprietary nucleos(t)ide prodrug platform to create candidates targeting ssRNA viruses like COVID-19, dengue, and hepatitis C.

BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington.

Details for the poster presentations are as follows:

Poster Number: 512 
Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with Bemnifosbuvir
Session: Pharmacokinetics/Pharmacodynamics of SARS-CoV-2 Therapeutics

Poster Number: 513 
Title: Bemnifosbuvir Has Low Potential to Inhibit P-gp, BCRP, and OATP1B1 Mediated Transport
Session: Pharmacokinetics/Pharmacodynamics of SARS-CoV-2 Therapeutics

About Atea Pharmaceuticals

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the clinical development of orally-available antiviral agents for difficult-to-treat, severe viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus and hepatitis C virus (HCV). For more information, please visit www.ateapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, including bemnifosbuvir combination product candidates, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for COVID-19, bemnifosbuvir and ruzasvir for the potential treatment of HCV and AT-752 for dengue. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

What are the upcoming presentations by Atea Pharmaceuticals at CROI 2023?

Atea Pharmaceuticals will present two posters at CROI 2023: Poster 512 on dose adjustments for CYP3A4 substrates and Poster 513 on bemnifosbuvir's potential to inhibit P-glycoprotein.

When is the CROI conference where Atea will present its research?

The CROI conference will take place from February 19-22, 2023, in Seattle.

What is the focus of Atea Pharmaceuticals' research?

Atea Pharmaceuticals focuses on developing oral therapies for severe viral diseases, particularly using its nucleos(t)ide prodrug platform.

What viral diseases is Atea targeting with its therapies?

Atea is targeting challenging viral infections such as COVID-19, dengue virus, and hepatitis C with its antiviral agents.

What is the stock symbol for Atea Pharmaceuticals?

The stock symbol for Atea Pharmaceuticals is AVIR.